{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:06:18Z","timestamp":1790053578980,"version":"4.0.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Merkel cell carcinoma (MCC) is a rare but highly aggressive cutaneous malignancy with limited epidemiological and therapeutic data in Asian populations. While immunotherapy works in Western patients, its efficacy in Chinese MCC patients remains unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 40 histologically confirmed MCC cases treated at our institution between November 2011 to November 2024. Sixteen patients with complete records underwent detailed analysis of demographics, treatments, and responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 25 female and 15 male patients (median age 71 years, range 25-91). Of the 16 patients with detailed information, 15 (94%) patients underwent extensive resection while 1 did not. Among surgical patients, 1 (7%) patient operative area received postoperative adjuvant radiotherapy, and 2 (13%) had additional lymph node dissection. Immunohistochemical analysis showed that out of 10 evaluable patients, 8 (80%) were MCPyV positive and 3 (30%) were PD-L1 positive. Among the patients receiving systemic treatment, four were administered Pembrolizumab at a dose of 200 mg every three weeks. Remarkably, three of these patients (75%) achieved a complete response (CR) by radiographic evaluation, with two of the treated specimens showed no residual malignant cells detected in post-treatment biopsy specimens. The treatment was well-tolerated, with no grade 3 or higher adverse events reported during the observation period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study describes MCC characteristics in Chinese patients, with preliminary indications of female predominance and favorable immunotherapy responses. The findings highlight the need for standardized treatment approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1948121","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:23:10Z","timestamp":1790050990000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics and immunotherapy in Chinese patients with Merkel cell carcinoma: a retrospective analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Ting","family":"Li","sequence":"first","affiliation":[{"name":"Departments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Cancer Prevention and Therapy","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Ren","sequence":"additional","affiliation":[{"name":"Departments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Cancer Prevention and Therapy","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingfan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Second Clinical Medical College, Binzhou Medical University","place":["Yantai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Liao","sequence":"additional","affiliation":[{"name":"Departments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Cancer Prevention and Therapy","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwu","family":"Ren","sequence":"additional","affiliation":[{"name":"Departments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Cancer Prevention and Therapy","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruwei","family":"Xing","sequence":"additional","affiliation":[{"name":"Departments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Cancer Prevention and Therapy","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Teng","sequence":"additional","affiliation":[{"name":"Departments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Cancer Prevention and Therapy","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yang","sequence":"additional","affiliation":[{"name":"Departments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Cancer Prevention and Therapy","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Departments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Cancer Prevention and Therapy","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Xing","sequence":"additional","affiliation":[{"name":"Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilong","family":"Yang","sequence":"additional","affiliation":[{"name":"Departments of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Cancer Prevention and Therapy","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-020-00428-5","article-title":"Patient experiences with avelumab in treatment-na\u00efve metastatic Merkel cell carcinoma: Longitudinal qualitative interview findings from JAVELIN Merkel 200, a registrational clinical trial","volume":"13","author":"Lambert","year":"2020","journal-title":"Patient - Patient-Centered Outcomes Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti\u2013PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"17077","DOI":"10.1038\/nrdp.2017.77","article-title":"Merkel cell carcinoma","volume":"3","author":"Becker","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2024.05.013","article-title":"Merkel cell carcinoma","volume":"38","author":"Strong","year":"2024","journal-title":"Hematology\/Oncology Clinics North America"},{"key":"B5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2017.10.028","article-title":"Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics","volume":"78","author":"Paulson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.07.065","article-title":"Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients","volume":"84","author":"Singh","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.11.020","article-title":"Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features","volume":"58","author":"Heath","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2024.05.013","article-title":"Merkel cell carcinoma","volume":"38","author":"Strong","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15292","article-title":"Merkel cell carcinoma: An updated review of pathogenesis, diagnosis, and treatment options","volume":"35","author":"Hernandez","year":"2022","journal-title":"Dermatol Ther"},{"key":"B10","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Merkel Cell Carcinoma. Version 1.2024","year":"2024"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cncr.22765","article-title":"Merkel cell carcinoma: Critical review with guidelines for multidisciplinary management","volume":"110","author":"Bichakjian","year":"2007","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.12.004","article-title":"Merkel cell carcinoma: An update and review: Current and future therapy","volume":"78","author":"Tello","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw042","article-title":"Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: Survival analyses of 6908 cases from the National Cancer Data Base","volume":"108","author":"Bhatia","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-013-0225-9","article-title":"Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma","volume":"14","author":"Miller","year":"2013","journal-title":"Curr Treat Options Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0184","article-title":"FDA accelerated approval of pembrolizumab for recurrent locally advanced or metastatic Merkel cell carcinoma","volume":"25","author":"Bradford","year":"2020","journal-title":"Oncologist"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/hed.70054","article-title":"Merkel cell carcinoma: Evolving therapeutics, continued challenges","volume":"47","author":"Holley","year":"2025","journal-title":"Head Neck"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/dad.0000000000002837","article-title":"Merkel cell carcinoma case reports with Merkel cell polyomavirus test and review of the literature","volume":"46","author":"Chai","year":"2024","journal-title":"Am J Dermatopathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00858-z","article-title":"Merkel cell carcinoma: Integrating epidemiology, immunology, and therapeutic updates","volume":"25","author":"Becker","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115489","article-title":"Prognostic role of tumoral PD-L1 and IDO1 expression, and intratumoral CD8+ and FoxP3+ lymphocyte infiltrates in 132 primary cutaneous Merkel cell carcinomas","volume":"22","author":"Donizy","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15205084","article-title":"An updated review of the biomarkers of response to immune checkpoint inhibitors in Merkel cell carcinoma: Merkel cell carcinoma and immunotherapy","volume":"15","author":"Fojnica","year":"2023","journal-title":"Cancers"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0103-2","article-title":"The biology and treatment of Merkel cell carcinoma: Current understanding and research priorities","volume":"15","author":"Harms","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01884-7","article-title":"Retifanlimab: first approval","volume":"83","author":"Kang","year":"2023","journal-title":"Drugs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1200\/jco.18.01896","article-title":"Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"S686","DOI":"10.1016\/j.annonc.2023.09.2280","article-title":"1146P Updated results from POD1UM-201: A phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC)","volume":"34","author":"Grignani","year":"2023","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.canlet.2020.02.036","article-title":"IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in Malignant melanoma","volume":"477","author":"Li","year":"2020","journal-title":"Cancer Lett"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.05251.x","article-title":"The clinical profile of Merkel cell carcinoma in mainland China","volume":"51","author":"Song","year":"2012","journal-title":"Int J Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112142-20230802-00022","article-title":"Clinical characteristics and research progress of ocular Merkel cell carcinoma","volume":"60","author":"Zhang","year":"2024","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad059","article-title":"Merkel cell carcinoma: A review of clinical management with focus on Asian patients","volume":"53","author":"Nakano","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcskn.2025.100755","article-title":"Clinical characteristics and treatments of Merkel cell carcinoma in Japan: A multi-center retrospective study","volume":"3","author":"Nakano","year":"2025","journal-title":"EJC Skin Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15875","article-title":"Merkel cell carcinoma: A systematic review of the demographic and clinical characteristics of 847 cases in Japan","volume":"48","author":"Shinogi","year":"2021","journal-title":"J Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04932-7","article-title":"Clinicopathological characteristics and prognosis of Merkel cell carcinoma: A single-center retrospective study in Korea","volume":"149","author":"Moon","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16716","article-title":"Epidemiology and survival analysis of Merkel cell carcinoma in South Korea: A nationwide, multicenter retrospective study","volume":"62","author":"Choi","year":"2023","journal-title":"Int J Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000017538","article-title":"Merkel cell carcinoma in Taiwan: A series of 24 cases and literature review","volume":"98","author":"Chang","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00432-024-05743-0","article-title":"Merkel cell carcinoma overlapping Bowen's disease: Two cases report and literature review","volume":"150","author":"Chen","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2024.09.019","article-title":"Merkel cell carcinoma in Taiwan: A subset is chronic arsenicism-related, and the Merkel cell polyomavirus-negative cases are pathologically distinct from virus-related cases with a poorer outcome","volume":"57","author":"Liu","year":"2025","journal-title":"Pathology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.815","article-title":"Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma","volume":"5","author":"Iyer","year":"2016","journal-title":"Cancer Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0072","article-title":"Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma","volume":"13","author":"Nghiem","year":"2017","journal-title":"Future Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.545","article-title":"545\u2005A phase 2 study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC) (POD1UM-201)","volume":"9","author":"Grignani","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1948121\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:23:12Z","timestamp":1790050992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1948121\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":41,"alternative-id":["10.3389\/fonc.2026.1948121"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1948121","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1948121"}}